Angionetics raised a round of funding on July 12, 2016. Investors include Huapont Life Sciences.

Angionetics develops and commercializes DNA-based therapeutics. The products are designed to promote the heart's capacity to modulate the formation and growth of cardiac microvascular circulation to e…